Merck KGaA to Acquire Silence Therapeutics for $1.3 Billion
The pharmaceutical giant plans to integrate new gene-silencing technology through an all-cash acquisition.
Updated on Oct. 20, 2026 in Healthcare
Live Poll
Do you believe large pharmaceutical company mergers lead to better access to new specialized medical treatments?
Merck KGaA has announced plans to purchase Silence Therapeutics in a deal valued at $1.3 billion. The acquisition includes Silence's siRNA medicines portfolio and their mRNAi GOLD platform.
Why it matters
The deal aims to bolster Merck's capabilities in targeting specialty and rare diseases by adding precision-engineered gene-silencing therapies to its existing portfolio.
Merck will pay $20 per share for Silence Therapeutics in an all-cash deal. This valuation follows other major moves, including a $3.9 billion purchase of SpringWorks Therapeutics in 2025 and a pending $11.3 billion acquisition of Bio-Techne.
The players
Merck KGaA
This German pharmaceutical and chemical company focuses on healthcare, life science, and electronics.
Silence Therapeutics
This biotechnology firm specializes in creating siRNA medicines designed to address gene-related diseases.
The details
The transaction will be completed through a UK scheme of arrangement to incorporate the mRNAi GOLD siRNA platform. This acquisition adds Silence's gene-silencing medicines, which switch off disease-related gene messages, including the lead candidate zerlasiran for patients with high lipoprotein(a).
Timeline
2025: Merck acquired SpringWorks Therapeutics for $3.9 billion.
October 19, 2026: Merck announced the acquisition of Silence Therapeutics.
Q1 2027: The acquisition is expected to close.
Market Landscape
This deal underscores the aggressive expansion of the gene-silencing sector as major players look to diversify beyond traditional drug manufacturing. It positions Merck to compete more effectively in the rare disease market by absorbing the mRNAi GOLD siRNA platform.
This merger signals an increase in the long-term availability of precision medicines for rare diseases that may eventually reach patients worldwide. While current retail prices remain unchanged, the consolidation could standardize treatment options for patients with high lipoprotein(a).
The takeaway
Large pharmaceutical firms continue to prioritize gene-based therapies to maintain competitiveness in the specialty medicine market. Investors should monitor how the integration of new platforms like mRNAi GOLD influences future drug development timelines.
What happens next
The acquisition is scheduled to close in the first quarter of 2027.
Further reading
Learn more about industry trends in Healthcare.
Live Poll
Do you believe large pharmaceutical company mergers lead to better access to new specialized medical treatments?
